In children with allergic asthma, omalizumab (an anti-IgE therapy) reduced the duration and frequency of rhinovirus infections and decreased the rate and severity of rhinovirus-induced exacerbations [66–68]. This evidence concerns the gene IGHE and allergic asthma.